Oric Pharmaceuticals Inc (ORIC)

$11.25 +1.11 (10.95%)
Market Cap 891.11M
Revenue (ttm) 0.00
Net Income (ttm) -127.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,033,812
Avg Vol 1,359,188
Day's Range N/A - N/A
Shares Out 97.39M
Stochastic %K 90%
Beta 1.36
Analysts Strong Sell
Price Target $21.00

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 388 5600
Address:
240 East Grand Avenue, 2nd Floor, South San Francisco, United States
Bastianini
Bastianini Jan. 14 at 4:59 PM
$ORIC Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jan. 14 at 4:39 PM
$ORIC 119% institutional ownership 🤔 and 33% short interest 21.5ish million shorted shares per fintel 🧐.... Cash runway till 2028 including 2 phase 3 interim readouts.... All of that together is anomalous.....
0 · Reply
Godwins26
Godwins26 Jan. 14 at 4:34 PM
2nd Watchlist $IVP up 300% $BKKT $TENX $CLOV $ORIC
0 · Reply
darioras
darioras Jan. 14 at 3:24 PM
$ORIC Entered!
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jan. 14 at 3:18 PM
$ORIC wtf okay I'm in...... @gscdefense eyes on
1 · Reply
BullJack
BullJack Jan. 14 at 3:17 PM
$ORIC climbing
0 · Reply
Bastianini
Bastianini Jan. 13 at 8:02 PM
$ORIC "Advancing two late-stage oncology drugs with pivotal data and trials"
0 · Reply
The1Albatross
The1Albatross Jan. 13 at 5:26 PM
$ORIC Vetting
0 · Reply
www_larval_com
www_larval_com Jan. 7 at 8:27 PM
Dufus here, $ORIC just reversed -3% lower to 5% (~1Mv) in the last few minutes, 01/16 options, follow for more volatility.
0 · Reply
notreload_ai
notreload_ai Jan. 7 at 2:26 PM
$REGN , $ERAS , $TARA , $DSGN , $ORIC ... Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities. https://notreload.xyz/biotech-upgrades-regeneron-erasca-tara-dsgn-oric/
0 · Reply
Latest News on ORIC
ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:35 PM EST - 1 day ago

ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

Jan 12, 2026, 8:30 AM EST - 2 days ago

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:05 PM EST - 8 days ago

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript

Dec 7, 2025, 1:38 AM EST - 5 weeks ago

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 5, 2025, 8:00 PM EST - 5 weeks ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2025, 4:30 PM EST - 5 weeks ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 5, 2025, 1:00 AM EST - 5 weeks ago

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Dec 4, 2025, 9:45 PM EST - 5 weeks ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Dec 3, 2025, 4:01 PM EST - 6 weeks ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Top 3 Health Care Stocks That May Rocket Higher In December

Dec 3, 2025, 6:45 AM EST - 6 weeks ago

Top 3 Health Care Stocks That May Rocket Higher In December

LRMR PRGO

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Dec 1, 2025, 8:00 AM EST - 6 weeks ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 7 weeks ago

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

Nov 13, 2025, 4:10 PM EST - 2 months ago

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

Nov 13, 2025, 4:05 PM EST - 2 months ago

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Nov 6, 2025, 4:00 PM EST - 2 months ago

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 4, 2025, 4:30 PM EST - 2 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

Oct 27, 2025, 8:30 AM EDT - 2 months ago

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 7:37 PM EDT - 4 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

Aug 18, 2025, 4:05 PM EDT - 5 months ago

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

Aug 12, 2025, 4:05 PM EDT - 5 months ago

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

May 29, 2025, 11:15 AM EDT - 8 months ago

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 28, 2025, 4:05 PM EDT - 8 months ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 28, 2025, 4:05 PM EDT - 8 months ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 27, 2025, 8:00 AM EDT - 8 months ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

May 5, 2025, 4:05 PM EDT - 9 months ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 9 months ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

Apr 22, 2025, 9:15 AM EDT - 9 months ago

ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 10 months ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Feb 25, 2025, 4:15 PM EST - 11 months ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Feb 18, 2025, 4:05 PM EST - 11 months ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 13, 2025, 8:05 AM EST - 1 year ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 1, 2024, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 9, 2024, 4:15 PM EDT - 1 year ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 12, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Aug 5, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 17, 2024, 1:00 PM EDT - 1 year ago

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

Jul 16, 2024, 4:59 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

May 6, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 15, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 8, 2024, 8:00 AM EDT - 1 year ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 13, 2024, 8:19 AM EDT - 2 years ago

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Mar 11, 2024, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

Mar 6, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

Feb 14, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Jan 22, 2024, 8:30 AM EST - 2 years ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Jan 8, 2024, 8:30 AM EST - 2 years ago

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Bastianini
Bastianini Jan. 14 at 4:59 PM
$ORIC Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jan. 14 at 4:39 PM
$ORIC 119% institutional ownership 🤔 and 33% short interest 21.5ish million shorted shares per fintel 🧐.... Cash runway till 2028 including 2 phase 3 interim readouts.... All of that together is anomalous.....
0 · Reply
Godwins26
Godwins26 Jan. 14 at 4:34 PM
2nd Watchlist $IVP up 300% $BKKT $TENX $CLOV $ORIC
0 · Reply
darioras
darioras Jan. 14 at 3:24 PM
$ORIC Entered!
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jan. 14 at 3:18 PM
$ORIC wtf okay I'm in...... @gscdefense eyes on
1 · Reply
BullJack
BullJack Jan. 14 at 3:17 PM
$ORIC climbing
0 · Reply
Bastianini
Bastianini Jan. 13 at 8:02 PM
$ORIC "Advancing two late-stage oncology drugs with pivotal data and trials"
0 · Reply
The1Albatross
The1Albatross Jan. 13 at 5:26 PM
$ORIC Vetting
0 · Reply
www_larval_com
www_larval_com Jan. 7 at 8:27 PM
Dufus here, $ORIC just reversed -3% lower to 5% (~1Mv) in the last few minutes, 01/16 options, follow for more volatility.
0 · Reply
notreload_ai
notreload_ai Jan. 7 at 2:26 PM
$REGN , $ERAS , $TARA , $DSGN , $ORIC ... Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities. https://notreload.xyz/biotech-upgrades-regeneron-erasca-tara-dsgn-oric/
0 · Reply
McMillion1
McMillion1 Jan. 6 at 3:11 AM
$ORIC $18
0 · Reply
UgoGreg
UgoGreg Dec. 28 at 10:25 PM
$ORIC https://youtu.be/pXFO9_cJJUM
0 · Reply
CH_Expat
CH_Expat Dec. 18 at 8:28 PM
$ORIC Interesting bloodbath here. At COGT I made a mistake and thought there were "reasons" when it traded at 200m EV. So worth watching.
1 · Reply
UgoGreg
UgoGreg Dec. 17 at 6:38 AM
$ORIC https://youtu.be/ygBN8MilTyc
0 · Reply
McMillion1
McMillion1 Dec. 11 at 2:57 AM
$FDMT $GOSS $ORIC
0 · Reply
McMillion1
McMillion1 Dec. 10 at 12:36 PM
$ORIC $GOSS $FDMT - 12 to 24 months
0 · Reply
CH_Expat
CH_Expat Dec. 8 at 5:17 PM
$ORIC What do you think of it at this levels?
1 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:50 PM
Wells Fargo updates rating for ORIC Pharmaceuticals ( $ORIC ) to Overweight, target set at 19 → 25.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:39 PM
Wedbush updates rating for ORIC Pharmaceuticals ( $ORIC ) to Outperform, target set at 20.
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 6 at 9:49 PM
$ORIC Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases "Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET"
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 5 at 1:42 PM
$ORIC (+1.6% pre) ORIC Pharmaceuticals reports 35% response rate for lung cancer drug https://ooc.bz/l/86421
0 · Reply
Trader1141
Trader1141 Dec. 5 at 12:09 PM
$ORIC Short Float over 30%…. If it starts moving 😍
0 · Reply